SEARCH:   Advanced

Blood, 1 April 2007, Vol. 109, No. 7, pp. 2700-2707. Prepublished online as a Blood First Edition Paper on November 21, 2006; DOI 10.1182/blood-2006-07-025809. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-07-025809v1 109/7/2700    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Jost, P. J. Articles by Ruland, J. Search for Related Content PubMed PubMed Citation Articles by Jost, P. J. Articles by Ruland, J. Related Collections Neoplasia Oncogenes and Tumor Suppressors Signal Transduction Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  REVIEW IN TRANSLATIONAL HEMATOLOGY Aberrant NF-B signaling in lymphoma: mechanisms, consequences, and therapeutic implications Philipp J. Jost1, and Jürgen Ruland1 1 III. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany The transcription factor NF-B is a tightly regulated positive mediator of T- and B-cell development, proliferation, and survival. The controlled activity of NF-B is required for the coordination of physiologic immune responses. However, constitutive NF-B activation can promote continuous lymphocyte proliferation and survival and has recently been recognized as a critical pathogenetic factor in lymphoma. Various molecular events lead to deregulation of NF-B signaling in Hodgkin disease and a variety of T- and B-cell non-Hodgkin lymphomas either upstream or downstream of the central IB kinase. These alterations are prerequisites for lymphoma cell cycling and blockage of apoptosis. This review provides an overview of the NF-B pathway and discusses the mechanisms of NF-B deregulation in distinct lymphoma entities with defined aberrant pathways: Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), mucosa-associated lymphoid tissue (MALT) lymphoma, primary effusion lymphoma (PEL), and adult T-cell lymphoma/leukemia (ATL). In addition, we summarize recent data that validates the NF-B signaling pathway as an attractive therapeutic target in T- and B-cell malignancies. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: G. Yan, J. Huang, N. R. Jarbadan, Y. Jiang, and H. Cheng Sequestration of NF-{kappa}B Signaling Complexes in Lipid Rafts Contributes to Repression of NF-{kappa}B in T Lymphocytes under Hyperthermia Stress J. Biol. Chem., May 2, 2008; 283(18): 12489 - 12500. [Abstract] [Full Text] [PDF] J. Ruland Signaling crosstalk in DLBCL Blood, April 1, 2008; 111(7): 3304 - 3304. [Full Text] [PDF] L. T. Lam, G. Wright, R. E. Davis, G. Lenz, P. Farinha, L. Dang, J. W. Chan, A. Rosenwald, R. D. Gascoyne, and L. M. Staudt Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma Blood, April 1, 2008; 111(7): 3701 - 3713. [Abstract] [Full Text] [PDF] S. V. Bradley, M. R. Smith, T. S. Hyun, P. C. Lucas, L. Li, D. Antonuk, I. Joshi, F. Jin, and T. S. Ross Aberrant Huntingtin Interacting Protein 1 in Lymphoid Malignancies Cancer Res., September 15, 2007; 67(18): 8923 - 8931. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020